Gastrointestinal Cancer

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

A recent study showed that a patient-navigation-based intervention may help increase the rate of CRC screening in typically underserved groups, including low-income, ethnically diverse patients.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

A vast majority of Medicare patients with cancer are receiving appropriate surgical care that is in line with current treatment guidelines.

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Investigators in a large cohort study reported that heavy alcohol consumption, particularly beer, significantly increases the risk of gastric cancer.

Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Janet Hampton from the University of Michigan Health System Cancer Center Explains the Distress Thermometer Study

Janet Hampton University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results

The FDA has approved Sutent (sunitinib) for the treatment of patients with unresectable, locally advanced, or metastatic pancreatic neuroendocrine tumors (pNET)

Janet Hampton Describes the Distress Thermometer

Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma

Certain patients whose cancer cells form mutations and build up a resistance to drugs, drive the need for second- and third-line therapies

Oncolytic viruses have the potential of killing cancer stem cells, particularly in cases of potentially fatal pancreatic cancer

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease

New data suggest that individuals who drink moderate amounts of alcohol have an increased likelihood of developing colorectal cancer

Spectrum Pharmaceuticals stock prices are the biggest story across the internet, not the FDA's approval of Fusilev

Aflibercept, an investigational angiogenesis inhibitor, improved overall survival as a second-line treatment for patients with mCRC

A class of drugs that has shown encouraging results in breast and ovarian cancers with BRCA gene mutations may also benefit patients who have colorectal cancers

Pfizer's sunitinib provides a favorable benefit-risk profile in patients with unresectable pancreatic neuroendocrine tumors (pNETs)

After much anticipation the Oncologic Drugs Advisory Committee has returned a verdict on Novartis' everolimus (Afinitor)

In 1993, William G. Cance, MD, was the first researcher to clone human focal adhesion kinase (FAK) and demonstrate its overexpression in metastatic cancers.

In this review article, the author discusses the use of tyrosine kinase inhibitors in the management of patients with gastrointestinal stromal tumors.

The results of a systematic review and meta-analysis suggest that the mortality risk for colon cancer patients begins to increase with any avoidable delay in adjuvant chemotherapy beyond 4 weeks.

Data from a large randomized trial showed that treatment with the targeted agent everolimus was associated with a 65% improvement in progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (PNETs).